COMMUNIQUÉS West-GlobeNewswire

Arialief Side Effects Investigated: Review the User Complaints, Top Benefits & Ingredients List Before Buy!
05/05/2025
New Review Explores Arialief’s Side Effects, Complaints, Ingredients, and Nerve-Calming Formula for Neuropathy Relief ALBANY, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- If you’re reading this, chances are you, or someone [...]
Arialief Reviews (CRITICAL INVESTIGATION) What Doctors Say About Arialief's Safety And Complaints!
05/05/2025
ALBANY, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Arialief is a thoughtfully designed natural nerve pain relief supplement that can address the root issues behind various symptoms associated with neuropathy. It is backed [...]
Coloplast A/S CEO Kristian Villumsen steps down as of today
05/05/2025
Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy period, the Board [...]
AB Science présentera lors de la réunion annuelle de l’ENCALS en 2025 de nouvelles données issues du programme de développement clinique du masitinib dans la SLA
05/05/2025
COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTERA LORS DE LA RÉUNION ANNUELLE DE L'ENCALS EN 2025 DE NOUVELLES DONNÉES ISSUES DU PROGRAMME DE DEVELOPPEMENT CLINIQUE DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE LE [...]
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
05/05/2025
PRESS RELEASE AB SCIENCE TO PRESENT NEW DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS IN TWO PRESENTATIONS AT THE 2025 ENCALS ANNUAL MEETING MASITINIB REDUCES SERUM NEUROFILAMENT LIGHT CHAIN (NFL [...]
Cuprina Holdings (Cayman) Limited Announces Pricing of $12 million Initial Public Offering
05/05/2025
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (“ CUPR ” or “the Company ”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the [...]
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
05/05/2025
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“ CUPR ” or “the Company ”), a biomedical and biotechnology company dedicated to the development and commercialization of [...]
Cuprina Holdings Announces Completion, Receipt of Certification and License, for IVF Media Production Facility Built in Collaboration with Ferti-Craft Pte Ltd.
05/05/2025
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“ Cuprina ” or “the Company ”), a biomedical and biotechnology company dedicated to the development and commercialization of [...]
OSE Immunotherapeutics annonce que plus de 90% des patients répondeurs ont maintenu une rémission symptomatique pendant la période d’extension sous Lusvertikimab
05/05/2025
OSE Immunotherapeutics annonce que plus de 90 % des patients répondeurs ont maintenu une rémission symptomatique pendant la période d’extension sous Lusvertikimab Bonne tolérance de Lusvertikimab pendant les 24 semaines [...]
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
05/05/2025
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period. Oral [...]
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
05/05/2025
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, [...]
IBA – ACQUISITION D’ACTIONS PROPRES
05/05/2025
Publication immédiate – 5 mai 2025 Louvain-la-Neuve, Belgique, 5 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam [...]
IBA – ACQUISITION OF OWN SHARES
05/05/2025
Immediate Release – May 5 th , 2025 Louvain-la-Neuve, Belgium, May 5 th , 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam [...]
Robert Olsen Receives Individual Achievement Award from the Healthcare Financial Management Association
05/05/2025
NASHVILLE, Tenn., May 05, 2025 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) today presented Robert Olsen with the 2025 Frederick C. Morgan Individual Achievement Award, honoring career-long [...]
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
05/05/2025
Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and [...]
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
05/05/2025
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1 Mature overall survival data builds on encouraging high [...]
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
05/05/2025
CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent [...]
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates
05/05/2025
UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed aflibercept in a pre- [...]
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
05/05/2025
Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May 05 [...]

Pages